research Selection Signatures for Fiber Production in Commercial Species: A Review
Genomic research can help improve the quality and production of natural fibers in animals.
Search
for
Sort by
Research
240-270 / 316 results 
research Human Hair Follicles Operate a Functional Peripheral Equivalent of the Hypothalamic-Pituitary-Somatotropic Axis Ex Vivo
Human scalp hair follicles can produce hormones and have a system similar to a brain-body communication network.
research How Our Microbiome Influences the Pathogenesis of Alopecia Areata
Our microbiome may affect the development of the hair loss condition Alopecia Areata, but more research is needed to understand this relationship.
research Drug Survival and Long-Term Outcome of Tofacitinib in Patients with Alopecia Areata: A Retrospective Study
Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.
research Adverse Events in Patients Treated With Jak-Inhibitors for Alopecia Areata: A Systematic Review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
research Delayed Granulomatous Eruption of the Nose Associated with Ruxolitinib
Ruxolitinib can cause a delayed skin reaction on the nose.
research Clinical and Genetic Aspects of Alopecia Areata: A Cutting Edge Review
Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.
research Androgens and Androgen Receptor in the Management of Skin Diseases
Understanding how androgens and their receptors work can lead to improved treatments for skin diseases.
research New Modalities in the Treatment of Refractory Alopecia Areata
New treatments focusing on immune pathways show promise for stubborn hair loss.
research Systematic Review and Indirect Treatment Comparisons of Ritlecitinib Against Baricitinib in Alopecia Areata
Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
research Case Report: Sequential Therapy with Dupilumab and Baricitinib for Severe Alopecia Areata with Atopic Dermatitis in Children
Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.
research Thrombophilia and Polycythemia in a Woman With Budd-Chiari Syndrome
A woman with Budd-Chiari syndrome improved after treatment and needs a liver transplant, highlighting the importance of considering non-criteria antiphospholipid syndrome in similar cases.
research Treatments for Alopecia Areata: A Network Meta-Analysis
The medicine baricitinib was found to notably improve hair regrowth in alopecia areata, but more research is needed on its side effects and other treatments.
research Advances In The Mechanism And New Therapies Of Alopecia Areata
New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
research Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials
Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
research Alopecia Areata in Latin America: Where Are We and Where Are We Going?
Alopecia areata needs more recognition and better treatment access in Latin America to improve patient care and outcomes.
research Alopecia Areata: A Review of Diagnosis, Pathogenesis, and the Therapeutic Landscape
New treatments for alopecia areata show promise, but standardized guidelines are needed.
research Updates From 2021 Virtual Dermatology Nurses' Association Convention
The convention discussed various skin conditions, treatments, and the importance of continuous learning in dermatology nursing.
research Smoking and the Skin: Effects and Therapeutic Potential
Smoking harms the skin, causing early aging and increasing cancer risk, but stopping smoking can improve skin health.
research A Comprehensive Literature Review of JAK Inhibitors in the Treatment of Alopecia Areata
JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
Tofacitinib may help treat severe hair loss, but more research is needed.
research Treatment of Chronic Alopecia Areata With Tildrakizumab: An Open-Label Pilot Study
Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
research Dermatological Problems and COVID-19
COVID-19 can cause skin problems and affect dermatology treatments, with recommendations for skin care and cautious use of certain drugs.
research Two Cases of Alopecia Areata Treated with Ruxolitinib: A Discussion of Ideal Dosing and Laboratory Monitoring
Ruxolitinib effectively and safely regrows hair in alopecia patients.
research Efficacy of Baricitinib in Patients With Various Degrees of Alopecia Areata Severity: Results From Brave-AA1 and Brave-AA2
Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
research Efficacy and Safety of Baricitinib in Adults with Alopecia Areata: Phase 3 Results from a Randomized Controlled Trial (BRAVE-AA1)
Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.
research A New Era for Alopecia Areata: New Treatments and Improved Knowledge of the Condition
Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
research Baricitinib Results in Eyebrow and Eyelash Growth in Patients With Alopecia Areata Who Do Not Achieve 20% or Less Scalp Hair Loss
Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
research Efficacy in Subgroups Related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
Baricitinib significantly improves hair regrowth in severe alopecia areata.
research Efficacy of Baricitinib in Patients With Different Degrees of Severe Alopecia Areata: 52-Week Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.